Logo

Appleton to Distribute Spartan's CYP2C19 Test Platform

Oct 09, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Spartan Biosciences today announced Appleton Medical will distribute its CYP2C19 testing platform in the central US.

The Spartan RX CYP2C19 System received 510(k) clearance from the US Food and Drug Administration in August. It provides test results from a cheek swab in less than one hour, and aids physicians in prescription decisions involving drugs metabolized by the CYP450 2C19 genetic pathway. They include anti-platelet drugs, beta blockers, and proton pump inhibitors.

Financial and other terms of the deal were not disclosed.

The test was CE marked as an in vitro diagnostic in late 2010, and Spartan has inked deals with several distributors for the test in Europe.

Filed under

PCR
Diagnostics
Business News
distribution agreement
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.